Insights
Working notes on regulated medical-device engineering.
Short pieces on combination products, risk management, design controls, and human factors — written for working RA, QA, and R&D leaders.
Lifecycle & Program Management
Why medical device development breaks down between user needs, engineering, and manufacturing
Most medical-device programs do not fail on the technology. They fail at the seams — where user needs, engineering, design controls, and manufacturing should integrate but don't. A practitioner's anatomy of where, why, and how to architect around it.
Combination Products
21 CFR Part 4 in practice: where combination-product programs actually stall
Combination-product programs rarely stall on the regulation itself. They stall on the interfaces between device design controls and drug CGMP. A practitioner's view of where the three predictable stall points are — and how to architect a streamlined CGMP system that survives a coordinated FDA inspection.
User Research & Design Controls
From user research to verifiable requirements: a lifecycle framework for medical-device teams
User research produces narrative; design controls require verifiable inputs. A practitioner's framework for translating user-research outputs into design inputs that satisfy 21 CFR 820.30(c), align with IEC 62366-1:2015 use specifications, and produce a verification plan that audits cleanly.
Manufacturing & Lifecycle
Manufacturing transfer readiness: the 12 things most medical-device teams miss
Design transfer under 21 CFR 820.30(h) is one of the most expensive seams in regulated-product development. The regulation is short; the readiness checklist is long. Twelve specific gaps practitioner teams should close before transfer — covering DHF, DFM, process validation under 820.75, supplier readiness, and inspection posture.
Regulatory & Quality
Design controls that survive audit: a practitioner's guide to 21 CFR 820.30
Design controls under 21 CFR 820.30 are not a paperwork exercise. The structural integrity of the program — design plan, inputs, outputs, verification, validation, transfer, changes, and DHF — is what survives an FDA inspection. A practitioner's view of how to architect a design-controls system that holds up under coordinated inspection.
Combination Products
Sustaining engineering for combination products: cost reduction vs. regulatory risk
Sustaining engineering on a combination product is the most underestimated phase in the lifecycle. Cost-reduction opportunities are real but every change traverses 21 CFR 820.30(i) design changes, ISO 14971 risk re-evaluation, and 21 CFR Part 4 cross-constituent impact. A practitioner's framework for evaluating sustaining changes against the cost / risk frontier.
Regulatory & Quality · Coming soon
ISO 14971:2019 risk-file architecture
How to structure a risk management file so hazard analysis, risk-control evidence, and post-production input integrate cleanly with design controls. (Coming soon.)
Subscribe via RSS.